Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study

Launched by BART RIJNDERS · Oct 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to quickly detect a type of mold infection called invasive aspergillosis (IA) in patients who have weakened immune systems, such as those with blood-related diseases. The researchers want to find out if they can identify specific genetic changes in the fungus that make it resistant to a common treatment called voriconazole. This is important because infections caused by resistant fungi can be very serious and may lead to higher mortality rates. The trial is focused on patients who are 18 years or older and have signs of a possible fungal infection in their lungs, confirmed by a CT scan.

If you or a family member are eligible and choose to participate, you will provide a blood sample, which the researchers will test for these genetic mutations. This could help doctors diagnose fungal infections more quickly, leading to better treatment outcomes. The trial is currently recruiting participants, and it is important to note that patients who cannot give consent are not eligible to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older.
• • Lung CT shows lesions that fulfil the EORTC/MSG radiological criteria of possible invasive fungal infection.
• • A bronchoalveolar lavage is planned or has been performed \<48hrs earlier
• Exclusion Criteria:
• • - Patients unable or unwilling to provide consent